Tag Archives: AML

June, 2016

  • 29 June

    Novartis and Xencor Enter $2.4 Billion Deal in Bispecific Antibodies

    MONROVIA, Calif., June 28, 2016 /PRNewswire/ — Xencor, Inc. (Xencor) (NASDAQ:XNCR) announced today that it has entered into a collaboration and license agreement with Novartis to develop and commercialize novel therapeutics, including XmAb®14045 expected to begin clinical development for acute myeloid leukemia in 2016; and XmAb®13676 also expected to begin …

  • 13 June

    FDA Grants Fast Track Status to GlycoMimetics’ AML Drug

    ROCKVILLE, Md.–(BUSINESS WIRE)–GlycoMimetics, Inc. (NASDAQ:GLYC) today announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its novel E-selectin antagonist GMI-1271 for treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) and elderly patients aged 60 years or older with AML. …

April, 2016

November, 2015

  • 2 November

    EC Approves Celgene’s Vidaza for Treatment of AML

    BOUDRY, Switzerland–(BUSINESS WIRE)– Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG) today announced that theEuropean Commission (EC) has approved VIDAZA® (azacitidine for injection) for the treatment of adult patients aged 65 years or older with acute myeloid leukaemia (AML) who are not eligible for haematopoietic stem cell …